Minted: - / 5000

4842 Naluzotan
421dbebd5340329f53327e70db08a5f9ce98bf741d970310b8347e8c16bbbad1

Properties

Background

Yellow
Bottle

Yellow
Cap

Orange
Syringe

Gray
Bubbles
No
Drops
No
Label
Leaf

Chemistry

Formula
C23H38N4O3S
Carbon
23
Polarity
Neutral

Naluzotan (INN, USAN; PRX-00023) is a serotonergic drug of the phenylpiperazine class that was under investigation by EPIX Pharmaceuticals Inc for the treatment of generalized anxiety disorder and major depressive disorder. It acts as a selective and potent 5-HT_1A receptor partial agonist, readily stimulating prolactin responses, though it has also been found to bind to and activate the σ receptor. Naluzotan was well tolerated in clinical trials, with more patients in the control group dropping out due to adverse effects than in the active group in one study. The most frequently reported side effect was headache in 15% of patients (compared to 10% for placebo). In addition, naluzotan demonstrated significant antidepressant and anxiolytic effects as per the HAM-D and MADRS and the HAM-A, respectively, in some trials, but in others it did not. In the end it was not found to be significantly superior enough to placebo and development was stopped.

From Wikipedia, the free encyclopedia. License: CC BY-SA.